INT201127

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 6
Disease Relevance 0.59
Pain Relevance 0.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (QRFPR) signal transducer activity (QRFPR)
Anatomy Link Frequency
blood 1
QRFPR (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 12 97.64 Very High Very High Very High
headache 42 69.20 Quite High
abdominal pain 6 10.16 Low Low
pruritus 12 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Obesity 30 96.32 Very High Very High Very High
Malaria 108 75.76 Quite High
Headache 42 69.20 Quite High
Dizziness 60 68.16 Quite High
Otitis Media 6 66.64 Quite High
Vomiting 30 12.40 Low Low
Diarrhoea 18 11.76 Low Low
Toxicity 42 11.16 Low Low
Abdominal Pain 6 10.16 Low Low
Anorexia 6 8.88 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
With AQ-13, the mean ± standard deviation QTc interval increased from 397 ± 16 ms at baseline to 407 ± 11 ms 4 h after the second dose (p = 0.025).
Positive_regulation (increased) of AQ-13
1) Confidence 0.21 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0
Four hours after drug administration, volunteers who received 600 mg CQ had a mean 16 ms (95% confidence interval [CI], 9 to 23 ms) increase in the QTc interval from baseline, in comparison to an 11 ms (95% CI,, 4 to 18 ms) increase after 600 or 700 mg AQ-13.
Positive_regulation (increase) of AQ-13
2) Confidence 0.21 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0
To compensate for the apparent lower bioavailability of AQ-13 and achieve similar systemic exposure (based on the AUC)—in order to compare the safety of AQ-13 and CQ—the AQ-13 dose was increased (adjusted) to 700 mg and compared with the 600 mg dose of CQ (Figure 3B and 3C).
Positive_regulation (increased) of AQ-13 associated with bioavailability
3) Confidence 0.21 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0.05
These results are also consistent with the preclinical studies, which suggested that the AEs of AQ-13 and CQ would be similar and that a dose adjustment would be necessary for AQ-13 because of its more rapid clearance [17,18].
Positive_regulation (necessary) of AQ-13
4) Confidence 0.15 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.08 Pain Relevance 0
On the other hand, for the 1,750 mg AQ-13, 1,500 mg CQ dose, after the therapeutic dose, the effects of AQ-13 and CQ on the QTc interval were parallel to their blood levels—that is, QTc prolongation was greatest 4 h after the second dose on day 2, which was the time of the peak blood levels for both drugs (Figures 4–6).
Positive_regulation (parallel) of AQ-13 in blood
5) Confidence 0.15 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0
All the 63 participants who received AQ-13 and the 63 who received CQ were analyzed for AEs, including those who withdrew before completing the intended dose.
Positive_regulation (received) of AQ-13
6) Confidence 0.15 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.51 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox